Hôpital Femme Mère Enfant
Bron, Rhônes, 69500, France
NCT Number: NCT07357844
The treatment of tuberculosis disease in children benefits from clear and up-to-date recommendations from the World Health organization. The research issues supported by the WHO mainly concern tuberculosis treatment implementation in areas of high incidence and low economic level. Pediatric cohorts in countries with high economic levels are rare, making it impossible to quantify and describe deviations from optimal recommendations. The French recommendations are mainly focused on screening cases of tuberculosis, without specific guidelines for care organization and recent practice evaluation.
The retrospective study of patients followed by the pediatric infectious disease team of the Hospices Civils de Lyon (HCL) would allow to quantify treatment successes and failures, and to describe these failures in a French pediatric tertiary care center. This retrospective analysis is part of an evolution of the pediatric infectious diseases' activity of HCL in 2024: structuring of the service with a full-time practitioner, establishment of multi-professional care with the involvement of psychologists and clinical pharmacists. This retrospective study will help to understand the causes of failure in French tertiary pediatric centers and to describe the expected benefits of a structured and multi-professional care to improve the treatment of pediatric tuberculosis diseases in France.
This study is active but is not currently recruiting participants.
Up to 18 year
All sexes
Observational
Bron, Rhônes, 69500, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2014-2024
Tuberculosis treatment outcome, per World Health organization definitions: failed, cured, completed, died, lost to follow-up, not evaluated, success
Time frame: 2024-2026
Compliance with anti-tuberculosis treatment
Time frame: 2024-2026
Compliance with follow-up consultations
Time frame: 2024-2026
Adapted anti-tuberculosis treatment dosage
Time frame: 2024-2026
Adverse effects attributed to anti-tuberculosis treatment
Time frame: 2024-2026
Microbiological failure
Time frame: 2024-2026
Extension of treatment
Time frame: 2024-2026
Modification of treatment regimen
Hospices Civils de Lyon
Other
Acronym: POTTER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07069387
Actinomycetales Infections, Bacterial Infections
Sungai Buloh, Selangor, Malaysia
View Trial DetailsNCT05342064
Actinomycetales Infections, Bacterial Infections
Mbabane, Eswatini
View Trial DetailsNCT04557176
Actinomycetales Infections, Bacterial Infections
Kampala, Uganda
View Trial DetailsNCT07737275
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
View Trial Details